Value of Incentive Spirometry in Routine Management of COPD Patients and Its Effect on Diaphragmatic Function
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COPD
- Sponsor
- Menoufia University
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- assessing the change in baseline percentage of diaphragmatic thickness fraction
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The incentive spirometer is a device that encourages patients, with visual and other positive feedback, to maximally inflate their lungs and sustain that inflation. However, its efficacy in patients with COPD has been little documented especially in diaphragmatic function. This study tried to assess the role of incentive spirometry on Spirometric functions, Sonographic diaphragmatic function, and the scale of dyspnea in COPD patients with exacerbation and with follow-up of these parameters after 2 months.
Detailed Description
Forty COPD patients were admitted with an acute exacerbation and the patients were divided randomly into 2 equal groups: the first used the incentive spirometer together with medical treatment (according to GOLD guidelines) for 2 months and the second received only medical treatment for 2 months. All participants, on admission, underwent assessment of mMRC dyspnea scale, spirometry, arterial blood gases, and diaphragmatic ultrasound. Then, a follow-up of the participants was done after 2 months with the same parameters and a comparison between both groups was done.
Investigators
Amal A. El-Koa
doctor
Menoufia University
Eligibility Criteria
Inclusion Criteria
- •confirmed cases of COPD according to the criteria GOLD
- •age more than 40 years
Exclusion Criteria
- •bad acoustic window by ultrasound
- •other chronic respiratory diseases
- •lung malignancy
- •recent major surgery
- •inability to complete or perform the study
- •patient refusal
Outcomes
Primary Outcomes
assessing the change in baseline percentage of diaphragmatic thickness fraction
Time Frame: 2 months
assessing the change from baseline percentage of diaphragmatic thickness fraction (%) using ultrasound to 2 months
change in arterial blood gases
Time Frame: 2 months
assessment the change in baseline PaO2 and PaCO2 (in mmHg) to 2 months
assessing the change in baseline diaphragmatic excursion in cm
Time Frame: 2 months
assessing the change from Baseline diaphragmatic excursion (in cm) using ultrasound to 2 months
assessing the change in baseline peak expiratory flow rate percentage
Time Frame: 2 months
assessing the change from baseline peak expiratory flow rate percentage (%) using spirometry to 2 months
assessing the change in baseline forced vital capacity percentage of predicted
Time Frame: 2 months
assessing the change from baseline forced vital capacity percentage of predicted (%) using spirometry to 2 months
assessing the change in baseline forced expiratory volume in 1st second/forced vital capacity percentage (%)
Time Frame: 2 months
assessing the change from baseline forced expiratory volume in 1st second/forced vital capacity percentage (%) using spirometry to 2 months
assessing the change in mMRC dysnea scale
Time Frame: 2 months
assessing the change in the severity of dyspnea by mMRC dysnea scale from baseline to 2 months. It is 5 statements giving grades from 0 to 4 with the higher the degree, the more severe the shortness of breath in patients with COPD